DELHI, India, March 13, 2017 /PRNewswire/ --
Scientists at Invictus Oncology Pvt. Ltd. have utilized a novel linkerchemistry to generate antibody-drug conjugates which act like 'magic bullets', a concept proposed by Nobel laureate, Paul Ehrlich. This technology can provide a targeted therapy to cancer patients whereby the antibody can
About Invictus Oncology Private Limited
Invictus Oncology is a biopharmaceutical company based in Delhi, India focused on the development of novel therapeutics for cancer treatment. Invictus was co-founded by Harvard Medical School's Dr. Shiladitya Sengupta and Padma Vibhushan Dr. Raghunath A. Mashelkar.
Invictus has assembled a world-class management and scientific team, alongside a Board of Directors and Scientific Advisory Board that collectively have a significant track record of conducting acclaimed scientific research, developing breakthrough products and building sustainable businesses. Invictus is backed by Navam Capital, Aarin Capital and Ratan Tata.
Media Contact: Monideepa Roy [email protected] Invictus Oncology Private Limited
SOURCE Invictus Oncology Private Limited
Subscribe to our Free Newsletters!
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...View All